| scholarly article | Q13442814 |
| P50 | author | Eric Dumonteil | Q37370310 |
| Ana Claudia Torrecilhas | Q41839175 | ||
| Maria Júlia Manso Alves | Q41839194 | ||
| Daria Mochly-Rosen | Q56073232 | ||
| Nir Qvit | Q58873393 | ||
| Pedro Martinez-Vega | Q64633983 | ||
| P2093 | author name string | Nancy A Federspiel | |
| Deborah Schechtman | |||
| Qianqian Miao | |||
| Armando Jardim | |||
| Darlene Aparecida Pena | |||
| Maria Jesus Ramirez-Sierra | |||
| Fabio Cesar Gozzo | |||
| Andrey V Malkovskiy | |||
| Ndao Momar | |||
| Eric Churchill | |||
| Christian Teh-Poot | |||
| Denise Aparecida Berti | |||
| Anna D Cunningham | |||
| Chrislaine Oliveira Soares | |||
| Lauren A Baron | |||
| Liying Annie Liang | |||
| P2860 | cites work | Chagas disease: "the new HIV/AIDS of the Americas" | Q21144502 |
| Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations | Q24520510 | ||
| Chagas disease in the 21st century: a public health success or an emerging threat? | Q24594371 | ||
| Improved tools for biological sequence comparison | Q24652199 | ||
| Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations | Q28088410 | ||
| Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? | Q29038941 | ||
| Control of neglected tropical diseases | Q29547285 | ||
| PANTHER: a library of protein families and subfamilies indexed by function | Q29547480 | ||
| Drug resistance in leishmaniasis | Q29616242 | ||
| The RACK1 homologue from Trypanosoma brucei is required for the onset and progression of cytokinesis | Q30480155 | ||
| Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor | Q33319607 | ||
| Trypanosomatid RACK1 orthologs show functional differences associated with translation despite similar roles in Leishmania pathogenesis | Q33934065 | ||
| Adaptor proteins in protein kinase C-mediated signal transduction | Q34095764 | ||
| A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. | Q34228426 | ||
| Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure | Q34386778 | ||
| Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. | Q34515509 | ||
| Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis | Q34645824 | ||
| Topical treatment for cutaneous leishmaniasis. | Q34714228 | ||
| Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice | Q34933050 | ||
| Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps | Q34974266 | ||
| The RACK1 scaffold protein: a dynamic cog in cell response mechanisms | Q34999716 | ||
| Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite | Q35189546 | ||
| Microwave-assisted synthesis of cyclic phosphopeptide on solid support | Q35209746 | ||
| Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs | Q35569073 | ||
| Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation | Q35919791 | ||
| Leishmania major LACK antigen is required for efficient vertebrate parasitization | Q36371532 | ||
| Drug discovery and development for neglected parasitic diseases | Q36654913 | ||
| Expression cloning of a protective Leishmania antigen | Q36701227 | ||
| Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis | Q37003631 | ||
| Protein kinase C, an elusive therapeutic target? | Q37141320 | ||
| Rationally designed peptide regulators of protein kinase C. | Q37271445 | ||
| Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities | Q37404837 | ||
| Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism | Q37613357 | ||
| Targeting Trypanothione Metabolism in Trypanosomatid Human Parasites | Q37782110 | ||
| Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis | Q38195310 | ||
| Therapeutic applications of the cell-penetrating HIV-1 Tat peptide | Q38256208 | ||
| Peptide therapeutics: current status and future directions | Q38275750 | ||
| Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell | Q38494545 | ||
| Leishmaniasis: treatment updates and clinical practice guidelines review | Q38574783 | ||
| A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug | Q39032576 | ||
| Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells | Q39836484 | ||
| Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein | Q41825252 | ||
| Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. | Q42215365 | ||
| Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi | Q42270726 | ||
| Adhesion and interiorization of Trypanosoma cruzi in mammalian cells | Q42825388 | ||
| In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. | Q43252625 | ||
| Ankyrin peptide blocks falcipain-2-mediated malaria parasite release from red blood cells | Q44459212 | ||
| Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. | Q44618895 | ||
| Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo | Q44642004 | ||
| Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein | Q44775680 | ||
| Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. | Q44899521 | ||
| Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfi | Q46841203 | ||
| Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. | Q50647596 | ||
| Leishmania mexicana: LACK (Leishmania homolog of receptors for activated C-kinase) is a plasminogen binding protein. | Q54617027 | ||
| Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides | Q56390180 | ||
| Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors | Q56894313 | ||
| Backbone cyclization: A new method for conferring conformational constraint on peptides | Q67702601 | ||
| Preparation of the very acid‐sensitive Fmoc‐Lys(Mtt)‐OH Application in the synthesis of side‐chain to side‐chain cyclic peptides and oligolysine cores suitable for the solid‐phase assembly of MAPs and TASPs | Q71820607 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 74-84 | |
| P577 | publication date | 2016-02-12 | |
| P1433 | published in | International Journal for Parasitology: Drugs and Drug Resistance | Q20181953 |
| P1476 | title | Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors | |
| P478 | volume | 6 |
Search more.